Volcano bids for assets

Article

Laguna Hills, CA-based Volcano Therapeutics has signed a letter of intent to acquire the global intravascular ultrasound and functional measurement businesses of Jomed, a high-tech medical research company headquartered in Helsingborg, Sweden. Bankruptcy

Laguna Hills, CA-based Volcano Therapeutics has signed a letter of intent to acquire the global intravascular ultrasound and functional measurement businesses of Jomed, a high-tech medical research company headquartered in Helsingborg, Sweden. Bankruptcy is forcing Jomed to divest its assets, some of which were sold to Abbott Laboratories in June. The company plans to sell the remainder in the coming months. Volcano Therapeutics has tagged several as complementary to its efforts to develop products for the detection and treatment of atherosclerosis and vulnerable plaques in the coronary and peripheral arteries. Jomed's IVUS technology is synergistic with Volcano's Virtual Histology IVUS system, recently demonstrated at the Paris Course on Revascularization, according to Scott Huennekens, Volcano president and CEO. The California company's intravascular thermography catheter products also promise to integrate well with the pressure catheter and flow wire interventional products of Jomed's functional measurement business, he said.

Recent Videos
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
Related Content
© 2025 MJH Life Sciences

All rights reserved.